RT Journal Article
SR Electronic
T1 COVID-19 trend in Bangladesh: deviation from epidemiological model and critical analysis of the possible factors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.31.20118745
DO 10.1101/2020.05.31.20118745
A1 Ahmed, Asif
A1 Rahman, Mohammad Mahmudur
YR 2020
UL http://medrxiv.org/content/early/2020/06/23/2020.05.31.20118745.abstract
AB Background Since its first report on March 08, COVID-19 positive cases and number of deaths are increasing in Bangladesh. In the first month of COVID-19 infection, incidence of daily positive cases did follow the susceptible, infected and recovered (SIR) based predictions we reported in April, but started to deviate in the following months. COVID-19 transmission and disease progression depends on multifaceted determinants e.g. viral genetics, host immunity, social distancing, co-morbidity, socio-demographic and environmental parameters. Therefore deviation in confirmed cases from predicted model may appear and warrant thorough investigation.Methods In this short report, we compared real data with SIR model and analyzed the possible factors associated with the deviation which included preventive intervention strategies, socioeconomic capabilities, climatic and meteorological indexes, acquired immunity of Bangladeshi population, demographic characteristics, health indicators and food habits.Results The key factor responsible for the observed deviation was found to be the number of tests performed. Having population with low median age, young age groups are being mostly infected. Low prevalence of non-communicable diseases among them and strong immunity compared to the elderly might have kept most of them asymptomatic with silent recovery. Warm temperature, humidity and UV index of Bangladesh during this summer period might have contributed to the slow progression of infection. Longer daylight mediated immunity, fresh air circulations and ventilation, less population density in rural areas and certain food habits perhaps helped the large number of populations to restrict the infection up to a level.Conclusion Despite all these helpful determinants in Bangladesh, person to person contact is still the leading risk factor for COVID-19 transmission. Infection may increase rapidly if safe distance and preventive measures are not strictly followed while resuming the normal social and work life. Expanding test capacity, strong collaborative action plans, strategies and implementation are needed immediately to prevent catastrophe.HighlightsLimited number of tests compared to large population was the key reason for possible low daily positive cases reported in Bangladesh.Controlled interventions viz. official leave; transport ban and social distancing had helped initially to slow down the transmission.Warm weather, high humidity and UV index, sunlight mediated immunity, fresh air circulations, low pollutions, food habit and heterologous immunity might have reduced the transmission capabilities of SARS-CoV-2.Having large number of young people with strong immunity might have kept most of the infected asymptomatic who recovered silently.Person to person contact still remain as key risk factor in COVID-19 transmission, so strict health measures should be in place even after reopening social activities to contain further transmission.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot applicable as no clinical trial was performedFunding StatementNo funding was received for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The work did not require any ethical approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSecondary data used and cited in this study are publicly available. Primary data will be available for researcher with proper citation.